Synthesis and anti-cancer activity of naphthalimide–organylselanyl conjugates
Beilstein Journal of Organic Chemistry · 09.03.2026 · 22 · 416-435
DOI: 10.3762/bjoc.22.29 ↗Kurz gefasst
Fachartikel in der Zeitschrift Beilstein Journal of Organic Chemistry, online erschienen am 09.03.2026. Verfasst von Rajkumar Ravi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, School of Advanced Sciences, VIT-AP University, Amaravati-522237, Andhra Pradesh, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VIT University.
Abstract (Originalsprache)
The structure-based approach remains a valuable tool for rapid and high-throughput drug discovery and lead optimisation. In this study, we report the in-silico modelling and anticancer activity of two 1,8-napthalimide (NAP) derivatives containing organyl selanyl groups. The organylselanyl function n -octylselanyl ( n -OctSe) or phenylselanyl (PhSe) was introduced at the 6-position of a naphthalimide structure having a conserved 3-(4-( tert -butyl)phenoxy)propyl function at the imide nitrogen. The resultant naphthalimide–organylselanyl conjugates, NAP-SePh and NAP-Se( n -Oct), were characterised using various spectroscopic techniques, including FTIR, ¹H, ¹³C, ⁷⁷Se NMR and high-resolution mass spectrometry (HRMS). NAP-SePh was structurally characterised by single-crystal X-ray diffraction analysis. The anticancer potential of the NAP-SePh and NAP-Se( n -Oct) was evaluated using an in vitro cell viability assay with MDA-MB-231 triple-negative breast cancer (TNBC) cells. The IC₅₀ values for compounds NAP-SePh and NAP-Se( n -Oct) were 27.92 ± 3 µM and 23.06 ± 3 μM, respectively. Molecular docking simulations revealed that NAP-SePh and NAP-Se( n -Oct) show binding affinities of −10.39 and −8.53 kcal/mol for the (1M17) active, and −10.66 and −10.59 kcal/mol for the (4HJO) inactive conformation of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) in which erlotinib, a well-known anticancer drug, binds.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, School of Advanced Sciences, VIT-AP University, Amaravati-522237, Andhra Pradesh, India.
ORCID-Profile: Rajkumar Ravi, Selvakumar Karuthapandi
Förderung
- VIT University
Zitieren
APA
Ravi, R., & Karuthapandi, S. (2026). Synthesis and anti-cancer activity of naphthalimide–organylselanyl conjugates. Beilstein Journal of Organic Chemistry, 22, 416-435. https://doi.org/10.3762/bjoc.22.29
Vancouver
Ravi R, Karuthapandi S. Synthesis and anti-cancer activity of naphthalimide–organylselanyl conjugates. Beilstein Journal of Organic Chemistry. 2026;22:416-435. doi:10.3762/bjoc.22.29
BibTeX
@article{Ravi2026,
author = {Ravi, Rajkumar and Karuthapandi, Selvakumar},
title = {Synthesis and anti-cancer activity of naphthalimide–organylselanyl conjugates},
journal = {Beilstein Journal of Organic Chemistry},
year = {2026},
volume = {22},
pages = {416--435},
doi = {10.3762/bjoc.22.29}
}
EUVIMED